A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Summary

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Timeline

Start

2003-05-13

Primary completion

2004-08-25

Completion

2006-06-15

Publications

• Background Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007 Jan;61(1):171-80. doi: 10.1111/j.1742-1241.2006.01246.x. Epub 2006 Dec 5.
• Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Ther. 2015 Mar;6(1):29-40. doi: 10.1007/s13300-015-0098-y. Epub 2015 Jan 30.

Drugs

Indications